{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:04:14Z","timestamp":1753891454766,"version":"3.41.2"},"reference-count":13,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T00:00:00Z","timestamp":1722384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270629, 82100177"],"award-info":[{"award-number":["82270629, 82100177"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Data on the management of patients aged more than 85\u2009years with chronic hepatitis C virus (HCV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) sequential infections are lacking.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The current study described the management of an older couple aged more than 85\u2009years with these above-mentioned two diseases treated with 12\u2009weeks of sofosbuvir\/velpatasvir (Epclusa<jats:sup>\u00ae<\/jats:sup>) and 5\u2009days of nirmatrelvir\/ritonavir (Paxlovid<jats:sup>\u00ae<\/jats:sup>) sequentially. The effectiveness and safety profiles were closely monitored during therapy and till 9\u2009months posttreatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In late March 2023, the husband with the main complaint of repeated gingival bleeding and asymptomatic wife were 86 and 85\u2009years old, and had HCV RNA levels of 91,800 and 6,630,000\u2009IU\/mL, respectively. On the fourth day of sofosbuvir\/velpatasvir treatment, the husband had a moderate headache, and the wife had severe headache and moderate fever and dizziness. We then found that their SARS-CoV-2 test results were positive. After careful consideration, the expert panel decided to treat the couple with oral nirmatrelvir\/ritonavir (300\u2009mg\/100\u2009mg, twice daily) beginning on the fifth day of sofosbuvir\/velpatasvir treatment for 5\u2009days. During the 5\u2009days of nirmatrelvir\/ritonavir treatment, the patient\u2019s symptoms and signs gradually improved, and the patient was negative for SARS-CoV-2 RNA on the fifth day of nirmatrelvir\/ritonavir therapy. Meanwhile, the husband\u2019s HCV RNA was not detectable after one week of sofosbuvir\/velpatasvir treatment till posttreatment month 9, and his ALT level was normal beginning at week 1 of sofosbuvir\/velpatasvir treatment. Moreover, the wife\u2019s HCV RNA was not detectable after week 4 of sofosbuvir\/velpatasvir treatment till posttreatment month 9. Notably, no other symptoms or signs occurred during the treatment or follow-up period, and other serum biochemical parameters remained stable until 9\u2009months after the discontinuation of sofosbuvir\/velpatasvir treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The older couple aged more than 85\u2009years with chronic HCV and SARS-CoV-2 sequential infection were safely cured by the sofosbuvir\/velpatasvir and nirmatrelvir\/ritonavir sequential treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>This study suggested that old age should not be a barrier to HCV\/SARS-CoV-2 treatment. Given that the proportion of older HCV-infected patients is increasing, clinical trials of direct-acting antiviral agents should include older HCV-infected individuals.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmicb.2024.1438827","type":"journal-article","created":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T04:41:44Z","timestamp":1722400904000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Curing of chronic hepatitis C combined with coronavirus disease 2019 in a couple over 85\u2009years old: a case series study"],"prefix":"10.3389","volume":"15","author":[{"given":"Qing-Lei","family":"Zeng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue-Yan","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ru-Yue","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-Jie","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,7,31]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"14","DOI":"10.24926\/iip.v10i3.2144","article-title":"Influential factors of successful hepatitis C treatment in elderly patients","volume":"10","author":"Andres","year":"2019","journal-title":"Innov. Pharm."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad319","article-title":"Hepatitis C guidance 2023 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection","author":"Bhattacharya","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.jhep.2021.05.016","article-title":"Real-world experience of serial serum levels of GS-331007 in chronic hepatitis C hemodialysis patients during and after sofosbuvir\/velpatasvir therapy","volume":"75","author":"Huang","year":"2021","journal-title":"J. Hepatol."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"5193","DOI":"10.26355\/eurrev_202005_21297","article-title":"Editorial \u2013 Sofosbuvir\/Velpatasvir as a combination with strong potential activity against SARS-CoV2 (COVID-19) infection: how to use direct-acting antivirals as broad-spectrum antiviral agents","volume":"24","author":"Izzi","year":"2020","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1136\/gutjnl-2020-323569","article-title":"Sofosbuvir\/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment","volume":"71","author":"Liu","year":"2022","journal-title":"Gut"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.jhep.2019.11.014","article-title":"Evolution of eGFR in chronic HCV patients receiving sofosbuvir-based or sofosbuvir-free direct-acting antivirals","volume":"72","author":"Liu","year":"2020","journal-title":"J. Hepatol."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"5771","DOI":"10.1038\/s41598-022-09741-5","article-title":"Efficacy and safety of the sofosbuvir\/velpatasvir combination for the treatment of patients with early mild to moderate COVID-19","volume":"12","author":"Messina","year":"2022","journal-title":"Sci. Rep."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","article-title":"EASL recommendations on treatment of hepatitis C: final update of the series","volume":"73","author":"Pawlotsky","year":"2020","journal-title":"J. Hepatol."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"502","DOI":"10.3390\/tropicalmed8110502","article-title":"Hepatitis C virus infection in the elderly in the era of direct-acting antivirals: evidence from clinical trials and real life","volume":"8","author":"Pugliese","year":"2023","journal-title":"Trop. Med. Infect. Dis."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.idc.2017.07.014","article-title":"Hepatitis C virus infection in the older patient","volume":"31","author":"Reid","year":"2017","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1093\/jac\/dkab152","article-title":"Efficacy and safety of sofosbuvir\/velpatasvir versus the standard of care in adults hospitalized with COVID-19: a single-Centre, randomized controlled trial","volume":"76","author":"Sayad","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"901826","DOI":"10.3389\/fmicb.2022.901826","article-title":"Clinical characteristics of omicron SARS-CoV-2 variant infection after non-mRNA-based vaccination in China","volume":"13","author":"Zeng","year":"2022","journal-title":"Front. Microbiol."},{"article-title":"Sofosbuvir-based therapy for late pregnant women and infants with severe chronic hepatitis C: a case series study. J. Med. Virol. 94, 4548\u20134553. doi: 10.1002\/jmv.27877","year":"2022","author":"Zeng","key":"ref13"}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2024.1438827\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T04:41:48Z","timestamp":1722400908000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2024.1438827\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,31]]},"references-count":13,"alternative-id":["10.3389\/fmicb.2024.1438827"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2024.1438827","relation":{},"ISSN":["1664-302X"],"issn-type":[{"type":"electronic","value":"1664-302X"}],"subject":[],"published":{"date-parts":[[2024,7,31]]},"article-number":"1438827"}}